Valvular & structural heart disease
1-Year Outcomes After Transcatheter Edge-to-Edge Repair in Degenerative MR Stratified by Extent of Cardiac Damage
Authors' conclusion
Results from the CLASP IID trial demonstrate benefit of M-TEER in DMR patients across all EMCD stages, including stage 4, with low major adverse events and all-cause mortality and comparable significant improvements in echocardiographic and quality-of-life outcomes at 1 year.
Study context
- Population
- Prohibitive surgical risk patients with 3+ or 4+ degenerative mitral regurgitation undergoing mitral valve transcatheter edge-to-edge repair (M-TEER)
- Participants
- 211 patients
- Comparison
- M-TEER outcomes by baseline extramitral cardiac damage stage
- Stages 0, 1, and 2n = 112
- Stage 3n = 28
- Stage 4n = 71
Primary result
As reported in the abstract
1-year clinical events by EMCD stage
- Major adverse events comparable among all stages
- P = 0.343
- All-cause mortality comparable among all stages
- P = 0.644
- HF hospitalization significantly different among stages
- P = 0.012
Further findings
Echocardiographic and quality-of-life outcomes by extramitral cardiac damage (EMCD) stage · 1 year
- Mitral regurgitation ≤1+ comparable among stages
- P = 0.474
- LV diastolic volume comparable among stages
- P = 0.619
- LV systolic volume comparable among stages
- P = 0.676
- Kansas City Cardiomyopathy Questionnaire score comparable among stages
- P = 0.335
- Significant improvements from baseline in all stages
- P < 0.05
Baseline characteristics by EMCD stage
- More advanced cardiac damage: more comorbidities, lower functional and quality-of-life measures, greater mitral regurgitation severity
Original publication
1-Year Outcomes After Transcatheter Edge-to-Edge Repair in Degenerative MR Stratified by Extent of Cardiac Damage. JACC Cardiovasc Interv. Published 10 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →